癌と免疫療法

そもそもガンとは?| 免疫細胞療法とは| ガン免疫療法4つの特長| ガンの治療法|

ガン免疫療法 文献集

●参考文献集

免疫療法

リンパ腫に関する血液培養

樹状細胞との表

Cancer regression in patients with metastatic melanoma
after the transfer of autologous antitumor lymphocytes

ガン臨床の現状把握のためのブックマーク(cancer information files) 免疫療法

ガンサポート情報センター どの治療法が優れているか、どのクリニックがよいか

●症例集

血管肉腫に対して活性化リンパ球療法を試みた一例

脊髄損傷に対する骨髄幹細胞投与

Title Author Journal Vol&Page Year Pub Med ID
固層化CD3抗体により活性化したT Cell(CD3-LAK)を用いた養子免疫療法 関根暉彬 Biotherapy 4(10): 1606-1613 1990  
Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies. Kimoto Y, Tanaka T, Tanji Y, Fujiwara A, Taguchi T.
Biotherapy. 8(1):41-50. 1994 7547080
Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. Haruta I, Yamauchi K, Aruga A, Komatsu T, Takasaki K, Hayashi N, Hanyu F.
J Immunother Emphasis Tumor Immunol. 19(3):218-23. 1996 8811496
Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K.
Int J Urol. 5(1):16-21. 1998 9535595
Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels. Ebina T, Ogama N, Shimanuki H, Kubota T, Isono N. Cancer Immunol Immunother. 52(9):555-60 2003 14627127
A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C. Surgery. 100(2):262-72. 1986 3526604
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. N Engl J Med. 316(15):889-97. 1987 3493432
Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW 2nd, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE, et al. J Clin Oncol. 8(10):1618-29. 1990 2213099
Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A. J Clin Oncol. 10(6):960-8. 1992 1588376
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al. J Natl Cancer Inst. 85(8):622-32. 1993 8468720
Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report. Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T, Yamazaki S, Hasegawa H, Suzuki K, Yamagata M, et al. Cancer. 68(11):2391-6. 1991 1657353
Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K, Itoh K. Clin Cancer Res. 6(12):4663-73 2000 11156218
Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Gomez GG, Hutchison RB, Kruse CA. Cancer Treat Rev. 27(6):375-402. 2001 11908930
A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Kimura H, Yamaguchi Y. Cancer. 80(1):42-9. 1997 9210707
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Lancet. 356(9232):802-7. 2000 11022927

1. Morse M, et al. A phase 1 study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clinical Cancer Research. 1999, 5: 1331-1338.

2. Brossart P, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000, 96: 3102-3108.

3.?Triozzi PL, et al. Intratumoural injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer. 2000, 89 (12): 2646-2654.

4. Kobayashi T, et al. Regression of lymph node metastases by immunotherapy using autologous breast tumor-lysate pulsed dendritic cells: report of a case. Surg Today. 2001, 31: 513-516.

5. Pecher G. et al. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer immunol Immunother. 2002, 8(11-12): 669-73.

6. Dees CE, et al. Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunol Immunother. 2004, 53: 777-785.

7.?Vonderheide RH, et al. Vaccination of cancer patients against telomerase induces functional antitumour CD8+ T Lymphocytes. Clinical Cancer Research. 2004, 10: 828-839.

8.?Avigan D, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Research. 2004, 10: 4699-4708.

9.?Svane IM, et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004, 53: 633-641.

10. Homma S, et al. Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur J Clin Invest. 2005, 35(4): 279-86.

11. Katano M, Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res. 2005, 25(6A): 3771-6.

12. Loveland BE, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma, Clin Cancer Res. 2006, 12(3): 869-877.